 |
인쇄하기
취소
|
4 biologic agents on hot market competition
Published: 2011-07-12 06:59:00
Updated: 2011-07-12 06:59:00
The domestic biological drugs market so far enjoyed by three companies - Abbott/Eisai's Humira, Johnson & Johnson’s Remicade (infliximab), Wyeth’s Enbrel (etarnercept) - may be encountered with a fierce competition when Bristol-Myers Squibb's Orencia (abatacept) jumps in.
Orencia, the second-line drug in clinical settings here, is the first biologic discovered and developed in Bristol-Myers ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.